FDA nanotech meeting
This article was originally published in The Rose Sheet
Executive Summary
Pre-registration for the Oct. 10 Nanotechnology Task Force public meeting on nanotechnology closed Sept. 29, however, there will be on-site registration on a first-come, first-served basis until the room capacity is reached, FDA announces in a Sept. 26 Federal Register 1notice. The meeting, which will address the types of nanotechnology material products under development in the areas of foods, drugs and cosmetics, will be held in the Natcher Auditorium at the National Institutes of Health campus in Bethesda, Md. FDA announced plans for the meeting in April (2"The Rose Sheet" April 17, 2006, In Brief)...
You may also be interested in...
FDA nanotech meeting
Agency will sponsor public meeting in mid-October on nanotechnology, FDA announces in April 13 Federal Register notice. Topics slated to be discussed include types of nanotechnology material products under development in the areas of cosmetics, foods, drugs and other FDA-regulated areas. Meeting also provides opportunity to evaluate "whether there are scientific issues that should be addressed; and any other issues about which the regulated industry, academia and the interested public may wish to inform FDA" concerning nanotechnology use, FDA notes. Details regarding date and time of meeting, which will be held in Washington, D.C., will be provided in a subsequent Federal Register notice, agency adds...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.